about
Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.ROS1 rearrangements define a unique molecular class of lung cancers.Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the InevitableRadiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry.Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatmentSWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet cheProspective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyondMolecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based RecommendationsCrizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncologyGastrointestinal malignancies harbor actionable MET exon 14 deletions.Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screeningMET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approvalFirst-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsFactors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ HybridizationALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.Heart rate decrease during crizotinib treatment and potential correlation to clinical response.Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification.Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.
P50
Q26778318-FDD707C7-053E-491B-B79D-EDD789779D5CQ27023383-02F7A1AE-783C-449C-94BB-127C8D43E0C8Q27851651-F4BB9DDF-9DCD-4B36-9DCF-A703A8310E50Q27851700-4E5D79F9-DD52-4C63-A211-029C2E98756EQ27851751-9B9E8BD8-D4BA-477E-8078-61DD46712219Q27853059-DF71168C-6F3F-49B8-B0BC-F0D06958A813Q27853089-946B83D1-8B56-4EED-90C3-8374469A963EQ27853139-A8FEEB9F-AFE4-4D5C-A95E-36071CBAD85FQ27853166-0E58BF5E-2195-41C2-937C-67971FBC3D4EQ27853299-409CAACF-41D5-4E46-9F40-A5FF4CA9B68AQ27853321-674FAC44-04EE-4A49-B5A3-AEA6B25D083FQ27853371-536C358B-3014-4428-8F70-5C18EB997B96Q28076376-694FBCCC-7C2B-4531-ADA1-700896C2C3E9Q30934527-DD9BE2AA-E96D-448C-BD27-A3630BF1E611Q31148420-B0227754-5C89-4B80-971A-BBA28FCD2195Q34127899-09527691-DFB8-4A35-AA73-15AD9CB66F71Q35006450-6B8BA947-30FC-46E5-9D85-612BA2F04E77Q35057308-183A6C1A-45D2-4500-AC3E-C69D99178D4BQ35151094-845AD5BD-589B-4093-8577-C09BC78F2858Q35586700-5EDFAFB2-5318-48EF-AA3C-EC3A6AD15AC3Q35596686-A5BFB33C-06BE-4019-99B7-578F7B0036C9Q36116307-C8173657-B93E-4D79-A0BF-64F3F9DD59D6Q36405628-E9F14596-FF4F-46F9-8A17-3EFE68013934Q36414027-3EC9A393-43F8-4B94-B54E-629673ED9521Q36414458-43E4F0DF-7F44-49C7-9D02-64AB319F23B6Q36427358-05056EB6-C8D8-4C9E-A42C-912EC0D46391Q36675561-00647C75-9DF7-4378-BA5B-6424C8305C86Q36797256-CFB40BCA-8638-4E11-9913-5A22917E1E41Q37017049-80EDDA84-5321-4F53-A0A3-73647D04C0D5Q37416902-1F5070D2-0FBD-41A9-8A07-0469DE707888Q37976901-401A18B4-A975-4466-A31A-C84A8FE18F0DQ37982440-A4AD7329-2578-415C-AEB2-E843AB11ECC5Q38002468-3DD43AB7-366C-41D9-956D-8AEFDD31025FQ38090594-7149A1BF-2E23-4116-8F77-718285791353Q38105532-3050A2A2-232E-439C-8054-FD05E16EB5D6Q38118794-94FE48D9-277F-4C88-A3EC-1E295540FE80Q38126246-073E5208-843D-4323-A82F-631050D9D8C5Q38197071-0B394807-83E0-43D7-AF66-DEB5DA1985F7Q38538138-93582AFF-F51F-4DE2-9437-05E360E839D9Q38669285-4CBC034D-2ECE-4A8A-A462-D5BDB6AEBBE9
P50
description
onderzoeker
@nl
name
Sai-Hong Ignatius Ou
@ast
Sai-Hong Ignatius Ou
@en
Sai-Hong Ignatius Ou
@sl
type
label
Sai-Hong Ignatius Ou
@ast
Sai-Hong Ignatius Ou
@en
Sai-Hong Ignatius Ou
@sl
prefLabel
Sai-Hong Ignatius Ou
@ast
Sai-Hong Ignatius Ou
@en
Sai-Hong Ignatius Ou
@sl